Vaxil Bio Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: -0.042x

Vaxil Bio Ltd cash flow conversion efficiency. Based on the latest financial reports, Vaxil Bio Ltd (VXL) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-28.00K ≈ $-20.25K USD) by net assets (CA$667.00K ≈ $482.50K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Vaxil Bio Ltd (2009–2024)

Cash flow conversion efficiency of Vaxil Bio Ltd from 2009 to 2024. This chart illustrates how Vaxil Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VXL stock price for real-time trading data and today's change.

Vaxil Bio Ltd Cash Flow Conversion Ratio Explained

Vaxil Bio Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Vaxil Bio Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vaxil Bio Ltd ranked by their cash flow conversion efficiency. Also see Vaxil Bio Ltd (VXL) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ImmuPharma PLC LSE:IMM	-2.979x
CARLYLE COMMODIT.CORP. F:BJ4	-0.183x
Tan Delta Systems PLC LSE:TAND	-0.245x
Premier Health of America Inc V:PHA	-0.010x
Manolete Partners PLC LSE:MANO	0.081x
Pennant International Group plc LSE:PEN	0.136x
Kazera Global PLC LSE:KZG	-0.206x
INLIF LIMITED Ordinary Shares NASDAQ:INLF	0.065x

Annual Cash Flow Conversion Efficiency for Vaxil Bio Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Vaxil Bio Ltd from 2009 to 2024. Review Vaxil Bio Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$716.00K ≈ $517.94K	CA$-240.00K ≈ $-173.61K	-0.335x	+46.76%
2023-12-31	CA$891.00K ≈ $644.54K	CA$-561.00K ≈ $-405.82K	-0.630x	+2.55%
2022-12-31	CA$1.14 Million ≈ $821.77K	CA$-734.00K ≈ $-530.96K	-0.646x	-1.33%
2021-12-31	CA$1.70 Million ≈ $1.23 Million	CA$-1.08 Million ≈ $-784.15K	-0.638x	+53.52%
2020-12-31	CA$804.00K ≈ $581.60K	CA$-1.10 Million ≈ $-797.89K	-1.372x	-234.20%
2019-12-31	CA$-583.00K ≈ $-421.73K	CA$-596.00K ≈ $-431.14K	1.022x	+147.16%
2018-12-31	CA$435.00K ≈ $314.67K	CA$-943.00K ≈ $-682.15K	-2.168x	-205.47%
2017-12-31	CA$-487.00K ≈ $-352.29K	CA$-1.00 Million ≈ $-724.11K	2.055x	+190.01%
2016-12-31	CA$656.00K ≈ $474.54K	CA$-1.50 Million ≈ $-1.08 Million	-2.284x	-179.41%
2015-12-31	CA$-217.00K ≈ $-156.97K	CA$-624.00K ≈ $-451.39K	2.876x	+176.91%
2014-12-31	CA$34.48K ≈ $24.94K	CA$-128.91K ≈ $-93.25K	-3.739x	-83.25%
2013-12-31	CA$187.94K ≈ $135.95K	CA$-383.44K ≈ $-277.37K	-2.040x	+10.43%
2012-12-31	CA$72.15K ≈ $52.19K	CA$-164.34K ≈ $-118.88K	-2.278x	-31.42%
2011-12-31	CA$264.09K ≈ $191.04K	CA$-457.76K ≈ $-331.14K	-1.733x	-211.04%
2010-12-31	CA$682.06K ≈ $493.39K	CA$-380.10K ≈ $-274.96K	-0.557x	-98.24%
2009-12-31	CA$515.90K ≈ $373.20K	CA$-145.03K ≈ $-104.91K	-0.281x	--

About Vaxil Bio Ltd

V:VXL Canada Biotechnology

Market Cap

$198.18K

CA$273.96K CAD

Market Cap Rank

#31364 Global

#1672 in Canada

Share Price

CA$0.10

Change (1 day)

-23.08%

52-Week Range

CA$0.10 - CA$0.29

All Time High

CA$0.70